AzTrials
AzTrials

SarcopeniaNCT03929458

Association of Uremic Sarcopenia and Mitochondrial Copy Number and Its Clinical Correlates

An observational study of Sarcopenia and Mitochondrial DNA, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sarcopenia is the decline of muscle mass and strength with age. Evidence suggests that oxidative stress and molecular inflammation play important roles in age-related muscle atrophy. Read more about this study

Who is it for?
Ages 20 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Sarcopenia, Mitochondrial DNA
How many people
160 participants
Where
1 siteTaiwan
Study dates
7 May 2019to 31 Dec 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months.

Who may be able to join

  • Both sexes aged between 20-90 years.
  • Received stable hemodialysis at least 3 months.
  • Written informed consent.

Who cannot join

  • patients with severe infections, severe heart disease and liver disease, malignancy, autoimmune disorders, severe malnutrition, or clinical conditions requiring oral nutrition supplements;
  • Inability to follow protocol.
  • Pregnancy or wishing/trying to get pregnant

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • Tungs' Taichung MetroHarbour Hospital

    Taichung

Other trials in Taiwan

About this study

Official title: Association of Uremic Sarcopenia and Mitochondrial Copy Number and Its Clinical Correlates in Taiwanese Hemodialysis Patients

Sarcopenia is the decline of muscle mass and strength with age. Evidence suggests that oxidative stress and molecular inflammation play important roles in age-related muscle atrophy. The two factors may interfere with the balance between protein synthesis and breakdown, cause mitochondrial dysfunction, and induce apoptosis. Sarcopenia, inflammation and oxidative stress is highly prevalent in hemodialysis patients and may contribute to mortality. The copy number of mitochondrial DNA (mtDNA) is affected by oxidative stress in blood circulation. This study aimed to test whether mtDNA copy number correlates with oxidative stress and some uremic toxins in nondiabetic hemodialysis(HD) patients. 200 nondiabetic hemodialysis patients and 50 healthy subjects will be enrolled. This study will be performed to investigate quantitative changes in mtDNA occur in HD patients with and without sarcopenia. Copy number of mtDNA in leukocyte DNA is determined by real-time polymerase chain reaction in HD patients and 50 age- and sex-matched control subjects. In addition, correlation of the alterations of albumin redox status, 8-isoprostane, plasma IL-6 ,LBP and TNF-a and as well as various uremic toxins will be performed.

Read the detailed description

Research design and methods Subjects In this study, we shall recruit 200 patients on maintenance hemodialysis. In addition, 50 age- and sex-matched subjects act as controls. The HD patients have been on stable dialysis for at least 3 months HD patients are being treated three times weekly with standard bicarbonate dialysis (Na 138 mmol/L, HCO3 35 mmol/L, K 1.5 mmol/L, Ca 1.25 mmol/L, Mg 0.75 mmol/L) and by high-flux HD with synthetic membranes (dialysis filters surface area: 1.7 to 2.1 m2). All HD patients enroll in our study will be tested with DEXA and handgrip strength. Demographic data will be collected and laboratory examination are conducted as listed below.

Biochemical Determinations Blood samples for laboratory testing were drawn from the venous end of a vascular access at the beginning of the hemodialysis session and then stored at -80°C until time of analysis. The high sensitive C-reactive protein (hsCRP) levels were determined by a commercial immunoturbidimetric assay using a Hitachi autoanalyzer (model 7170). The detection limit and interval for CRP was 0.1 mg/L and 0.1-500.0 mg/L, respectively. The baseline serum albumin was measured by the bromocresol green method on a Hitachi autoanalyzer (model 7170). Serum levels of cholesterol, triglyceride, and low- and high-density lipoprotein cholesterol were determined by standard laboratory methods.

Determination of relative leucocyte mtDNA copy number The real-time PCR reaction was performed in triplicate for each reaction. The 10ul PCR reaction contains 1X TaqMan Universal PCR Master Mix buffer, 500nM of each primer, 200nM of TaqMan probe, and 0.2-2ng of total genomic DNA extract, PCR conditions are 2 min at 50℃, 10 min at 95℃, followed by 40 cycles of 15 s of denaturation at 95℃ and 60 s of annealing/extension at 60℃. Real-time quantitative analysis was performed on StepOne Real-Time PCR system(ABI). The primers and probes for real-time PCR are listed in Table 1. The PCR products that involve mitochondria DNA(MtDNA) and nuclear DNA.

Standard Curve:

Standard DNA solutions for the mitochondrial genome and the nuclear 18S rRNA dene (nDNA) were generated from PCR products cloned in a vector of pCR2.1-TOPO. Serial dilutions were made and RT-QPCR reactions were performed to construct the standard curve from Ct values and the number of copies of the standard plasmid DNA.

Determination of mtDNA/nDNA Ratio as a measure of mtDNA Content:

The copy number of the mtDNA and the nDNA is calculated using the threshold cycle number (Ct) and intrapolating from the standard curve. The ratio of the copy number of mtDNA to the copy number of nDNA is measurement of mtDNA content.[30] Measurement of the Albumin Redox State Measurement of the albumin redox state was performed using the high-performance liquid chromatography (HPLC) method reported previously [31]. The HPLC-fluorescence detection (HPLC-FD) system consisted of an AS-8010 autosampler (injection volume, 2 mL per specimen; Tosoh, Tokyo, Japan) and a Model FS-8000 fluorescence detector (excitation wavelength, 280 nm; emission wavelength, 340 nm) with a CCPM double-plunger pump (Tosoh) in conjunction with a SC-8020 system controller (Tosoh). A Shodex-Asahipak ES-502N 7C column [Showa Denko, Tokyo, Japan; 10×0.76 cm (inner diameter), dimethylaminoethyl-form for ion-exchange HPLC, column temperature, 35°C±0.5°C] or in some instances two Asahipak GS-520H columns [Asahi Chemical Industry; Kawasaki, Japan; 25×0.75 cm (inner diameter) maintained at 32°C] were used. Linear gradient elution was carried out with an ethanol level increasing from 0% to 5% in 0.05 M sodium acetate and 0.40 M sodium sulfate buffer (pH 4.85; acetate-sulfate buffer) at a flow rate of 1.0 mL/min. Deaeration of the buffer solution was performed by helium bubbling. Based on the HPLC profiles of HSA obtained from these procedures, the values for each fraction were subjected to numerical curve fitting, and the fractions of HMA, HNA-1, and HNA-2 to total HSA were calculated.

Measurements of Liposaccharide-binding protein (LBP) The LBP was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods, and serum from normal control subjects was used for interassay variation.

Total of 8-iso-PGF2-alpha Analysis Total 8-iso-PGF2-alpha concentrations in plasma were measured by a specific enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, Mich). Samples were centrifuged and the supernatants were collected, purified as stated previously and stored at -80°C until assayed. Samples were assayed at 50 μl after a 1:10 or 1:20 dilution and read at 420 nm in a 96 well microplate reader. The assay has been validated to obtain a high correlation (0.95) between added known amounts of 8-isoprostane and the concentration measured by EIA and has been directly validated by gas chromatography/mass spectrometry. The antiserum used in this assay has a 100%cross reactivity with 8-iso-PGF2-alpha 0.2% each with PGF2-alpha, PGF3, PGE1, PGE2, 0.1% each with 6-keto-PGF1-alpha. The detection limit of the assay is 4 pg/ml and the range of standard curve was from 3.9 to 500 pg/ml.

Measurements of Serum total p-cresol and Indoxyl sulfate Plasma concentrations of total p-cresol sulfate(PCS) and indoxyl sulfate( IS) are analyzed with High-performance liquid chromatography (HPLC). Briefly, for binding competition, 200μl serum to which we added 20μl 0.50mM 1-naphthalenesulfonic acid (internal standard) was vortex-mixed with 250μl 0.24M sodium octanoate (binding competitor).After incubation at room temperature for 5min, we added 2ml cold acetone to precipitate proteins. Following vortex-mixing and centrifuging at 4 ◦C, 1860×g for 20 min, the supernatant was transferred to 12mm×100mm, GL 14 glass test tubes and 2ml dichloromethane was added. After vortex-mixing and centrifuging at 4 ◦C, 1860×g for 10min, 200μl of the upper layer was transferred to glass autosampler vials, followed by addition of 20μl 1M HCl and 15μl was injected onto the HPLC. The HPLC analysis was performed on an Agilent 1100 series LC (Santa Clara, CA), and Agilent ChemStations software were used for the chromatographic analysis. The separation was carried out on a ZORBAX SB-C18 Solv Saver Plus HPLC column (5 μm, 3.0 mm×150 mm).at a flow rate of 0.6 ml/min. Mobile phase A is 0.2% trifluoroacetic acid in Milli-Q water and mobile phase B is 0.2% trifluoroacetic acid in acetonitrile. The analytical method consists of an isocratic run with 92% mobile phase A for 23 min.. Each analytical run was followed by a 1.3 min washout gradient to 100% B. Column temperature was 25 ◦C, and autosampler tray temperature was 6 ◦C. We quantified the analytes by using the analyte to standard peak area ratio on a Agilent 1100 High Performance Fluorescence detector G1321A. Detector settings were λex 260 nm/λem288nm for p-cresyl sulfate and λex 280 nm/λem 390nm for indoxyl sulfate and internal standard. Quantitative results are obtained and calculated in terms of their concentrations (mg/L).

Handgrip strength Muscle strength is assessed in the dominant hand using a Jamar hand dynamometer (Lafayette Instrument Company, USA). Patients are first familiarized with the device and were then examined standing with both arms extended sideways from the body with the dynamometer facing away from the body. Patients were instructed to grip the dynamometer with the maximum strength in response to a voice command, and the highest value of three measurements was considered for the study. Handgrip strength (HGS) values under the 30th percentile (Table 2) from a specific-population reference value adjusted for age and sex were considered as reduced [32].

Dual-Energy X-ray Absorptiometry (DEXA) DEXA is a widely used reference method for body FFM and FM measurements.10 DEXA was performed using a Lunar Prodigy (GE Medical Systems, Madison, WI). Whole-body scans were performed according to manufacturer's instructions, and body FM (FMDEXA), LTM (LTMDEXA) and bone mineral content are analyzed using the manufacturer's software. The DEXA method uses an X-ray tube with a filter to generate low-energy (40 kV). and high-energy (70 or 100 kV) photons. When photonsat different energy levels pass through tissue, their absorptions can be expressed as a ratio of attenuation at lower or higher energy levels. DEXA estimate of FFM was calculated as a sum of LTM and bone mineral content estimates.

All patients will be examined by the same observer. Overall, AWGS recommends using 2 standard deviations below the mean muscle mass of young reference group or the lower quintile as the cutoff value determination. Moreover, AWGS recommends using height-adjusted skeletal muscle mass instead of weight-adjusted skeletal muscle mass, and the suggested cutoff values were 7.0 kg/m2 in men and 5.4 kg/m2 in women by using DEXA.

Keywords
oxidative stress, Sarcopenia, copy number of mitochondrial DNA (mtDNA)
Medical subject headings
Sarcopenia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determination of mtDNA/nDNA Ratio as a measure of mtDNA Content

    The copy number of the mtDNA and the nDNA is calculated using the threshold cycle number (Ct) and intrapolating from the standard curve. The ratio of the copy number of mtDNA to the copy number of nDNA is measurement of mtDNA content.

    Measured: 1 years

Secondary outcomes (6)
  1. Plasma uremic toxins analysis

    ndoxyl sulfate (IS) and para-cresol (p-cresol) belong to the group of protein-bound uremic toxins that are poorly cleared by dialysis and are associated with poor clinical outcomes.the group of protein-bound uremic toxins that are poorly cleared by dialysis and are associated with poor clinical outcomes.

    Measured: 1 years

  2. Total of 8-iso-PGF2-alpha Analysis

    Total 8-iso-PGF2-alpha concentrations in plasma were measured by a specific enzyme immunoassay (EIA) kit

    Measured: 1 years

  3. Analysis of biomarkers of IL-6

    The IL-6 was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods

    Measured: 1 years

  4. Analysis of biomarkers of TNF-α

    The TNF-α was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods

    Measured: 1 years

  5. Analysis of biomarkers of Liposaccharide-binding protein (LBP)

    The LBP was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods

    Measured: 1 years

  6. Measurement of the Albumin Redox State

    the fractions of HMA, HNA-1, and HNA-2 to total HSA were measured using HPLC

    Measured: 1 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Apr 2019
  2. Study start7 May 2019
  3. Primary completion31 Dec 2019
  4. Study completion31 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Cross-sectional
Enrolment
160 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03929458
Sponsor's protocol ID
107061
Status last verified
Mar 2020
First submitted
22 Apr 2019
Last updated
11 Mar 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Sarcopenia and Mitochondrial DNA, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determination of mtDNA/nDNA Ratio as a measure of mtDNA Content (time frame: 1 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in